Skip to main content
SpringerLink
Log in

Zweitlinientherapie des nicht-kleinzelligen Bronchialkarzinoms

Tyrosinkinasehemmer bei ROS1-NSCLC-Subtyp offenbar gut wirksam

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Clinical Lung Cancer Genome Project, Network Genomic Medicine (2013) A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153.

  2. Bergethon K, Shaw AT, Ou S-HI, et al. (2012) J Clin Oncol 30:863–870.

    Article  CAS  Google Scholar 

  3. Bos M, Gardizi M, Schildhaus HU (2013. Lung Cancer 81:142–1433.

    Article  CAS  Google Scholar 

  4. Warth A, Muley T, Dienemann H et al (2014). Histopathology 65(2):187–194.

    Article  Google Scholar 

  5. National Comprehensive Cancer Network (2015) Non-small cell lung cancer. Version 3.2015.

  6. Shaw AT, Ou SH, Bang YJ, et al. (2014) N Engl J Med 371:1963–1971, 2014

    Article  Google Scholar 

  7. Garen E, et al. (2014) Lancet 384.665–673.

    Article  Google Scholar 

Literatur

  • Mazières J, Zalcman G, Crinò L, et al. Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. J Clin Oncol 2015;33:992–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik Schillerhöhe, Zentrum für Pneumologie, Thoraxchirurgie und Beatmungsmedizin, Solitudestr. 18, 70839, Gerlingen, Deutschland

    Martin Kohlhäufl

Authors
  1. Martin Kohlhäufl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Kohlhäufl.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kohlhäufl, M. Tyrosinkinasehemmer bei ROS1-NSCLC-Subtyp offenbar gut wirksam. Pneumo News 7, 30–31 (2015). https://doi.org/10.1007/s15033-015-0190-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-015-0190-z

Search

Navigation